AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11597949 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E at 300 mg/d on an empty stomach (group A)
Number of subjects: 20
Study 10518852 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Mouth and Gum Therapy
Number of subjects: 20
Study 10518852 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridex
Number of subjects: 20
Study 10518852 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 20
Study 10518852 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 20
Study 8624429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate 600 micrograms/daily
Number of subjects: 40
Study 8624429 — intervention group
Group type: COMPARATOR
Intervention: D-Trp6-LHRH 0.5 mg/daily
Number of subjects: 40
Study 2722135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fructose load
Number of subjects: 12
Study 2722135 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose load
Number of subjects: 12
Study 141471 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized atropine sulfate (1 mg)
Number of subjects: 20
Study 141471 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1000 (40 microgram and 80 microgram)
Number of subjects: 20
Study 141471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31733926 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB1, -DQA1, -DPB1, and -DPA1 genotyping
Number of subjects: 1064
Study 31733926 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DPB1 matching
Number of subjects: 1064
Study 31871257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping therapy application with two suctions, performed once a week for 8 weeks.
Number of subjects: 90
Study 31871257 — intervention group
Group type: COMPARATOR
Intervention: Placebo dry cupping therapy, performed once a week for 8 weeks.
Number of subjects: 90
Study 28558502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranger drug‐coated balloon (DCB)
Number of subjects: 105
Study 28558502 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated balloon angioplasty)
Number of subjects: 105
Study 25645167 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 43
Study 25645167 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 43
Study 23986166 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formula containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water applied twice daily for 4 weeks as monotherapy
Number of subjects: 102
Study 23986166 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formula applied twice daily for 8 weeks as adjunctive therapy
Number of subjects: 102
Study 23986166 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 8 weeks
Number of subjects: 102
Study 21074790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg desmopressin orally at bedtime
Number of subjects: 115
Study 21074790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20120751 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid fast-track anesthesia (bupivacaine-ketamine)
Number of subjects: 75
Study 20120751 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid fast-track anesthesia (bupivacaine-fentanyl)
Number of subjects: 75
Study 20120751 — intervention group
Group type: COMPARATOR
Intervention: Conventional general anesthetic technique (Control)
Number of subjects: 75
Study 18051713 — intervention group
Group type: EXPERIMENTAL
Intervention: xMAP technology
Number of subjects: 1061
Study 18051713 — intervention group
Group type: COMPARATOR
Intervention: hc2
Number of subjects: 1061
Study 15196307 — intervention group
Group type: EXPERIMENTAL
Intervention: Training module and administration of the guideline (Arm 1)
Number of subjects: 252
Study 15196307 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of guideline without training (Arm 2)
Number of subjects: 252
Study 15196307 — intervention group
Group type: COMPARATOR
Intervention: Current practice (Control Arm 3)
Number of subjects: 252
Study 11758228 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (Tpo) levels in CITP patients
Number of subjects: 33
Study 11758228 — intervention group
Group type: COMPARATOR
Intervention: Thrombopoietin (Tpo) levels in aplastic anemia (AA) patients
Number of subjects: 33
Study 11758228 — intervention group
Group type: COMPARATOR
Intervention: Thrombopoietin (Tpo) levels in acute myelogenous leukemia (AML) patients
Number of subjects: 33
Study 11758228 — intervention group
Group type: COMPARATOR
Intervention: Reticulated platelet count (RPC) in AA and AML patients
Number of subjects: 33
Study 11758228 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulated platelet percentage (RP%) in CITP and AML patients
Number of subjects: 33
Study 11758228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpo levels in CITP patients with glucocorticoid therapy response
Number of subjects: 33
Study 9127923 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with 20 ml of 0.25% bupivacaine
Number of subjects: 40
Study 9127923 — intervention group
Group type: COMPARATOR
Intervention: No epidural blockade
Number of subjects: 40
Study 8179049 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually computer‐tailored nutrition messages
Number of subjects: 0
Study 8179049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored nutrition information based on the 1990 Dietary Guidelines for Americans
Number of subjects: 0
Study 8179049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 3284457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (30 mg/kg)
Number of subjects: 6
Study 3284457 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone (30 mg/kg)
Number of subjects: 6
Study 29570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garments (CG)
Number of subjects: 16
Study 29570601 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 28601820 — intervention group
Group type: EXPERIMENTAL
Intervention: Innominate artery cannulation
Number of subjects: 110
Study 28601820 — intervention group
Group type: COMPARATOR
Intervention: Axillary artery cannulation
Number of subjects: 110
Study 25637271 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy device (ultrasonically activated device and bipolar vessel sealing device)
Number of subjects: 212
Study 25637271 — intervention group
Group type: COMPARATOR
Intervention: No energy device (control group)
Number of subjects: 212
Study 25637271 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy device
Number of subjects: 212
Study 23216423 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg
Number of subjects: 96
Study 23216423 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban 140 mg
Number of subjects: 96
Study 23216423 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 96
Study 23216423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 21134018 — intervention group
Group type: EXPERIMENTAL
Intervention: Movie with alcohol portrayal
Number of subjects: 122
Study 21134018 — intervention group
Group type: COMPARATOR
Intervention: Movie with no alcohol portrayal
Number of subjects: 122
Study 19238715 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC) for 10 min before the injection and during the procedure
Number of subjects: 100
Study 19238715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 16572350 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (NE)
Number of subjects: 25
Study 16572350 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 25
Study 16572350 — intervention group
Group type: EXPERIMENTAL
Intervention: Head‐up tilt
Number of subjects: 25
Study 16572350 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐Pugh scale
Number of subjects: 25
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day)
Number of subjects: 292
Study 12944340 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg/day)
Number of subjects: 292
Study 12944340 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (30 mg/day)
Number of subjects: 292
Study 12944340 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide (400 mg/day)
Number of subjects: 292
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine plasma concentrations
Number of subjects: 292
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment Hamilton depression scale scores
Number of subjects: 292
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout rates and side effects
Number of subjects: 292
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic effects of treatment
Number of subjects: 292
Study 12944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between plasma concentrations, gender, and therapeutic outcome
Number of subjects: 292
Study 10958603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55
Study 10958603 — intervention group
Group type: COMPARATOR
Intervention: No atropine (Control)
Number of subjects: 55
Study 9211675 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of elemental calcium
Number of subjects: 4589
Study 9211675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study 7999735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 22
Study 7999735 — intervention group
Group type: COMPARATOR
Intervention: Miniplate osteosynthesis
Number of subjects: 22
Study 2973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Megace
Number of subjects: 0
Study 2973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Megace plus DES
Number of subjects: 0
Study 2973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilphostrol
Number of subjects: 0
Study 2973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin
Number of subjects: 0
Study 31735141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2325
Study 31735141 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend sign
Number of subjects: 2325
Study 31735141 — intervention group
Group type: EXPERIMENTAL
Intervention: Black hole sign
Number of subjects: 2325
Study 31735141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodensities
Number of subjects: 2325
Study 31735141 — intervention group
Group type: EXPERIMENTAL
Intervention: Island sign
Number of subjects: 2325
Study 31097181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training
Number of subjects: 110
Study 28682183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat Dietary Modification (DM), N = 19,540, average duration 8.1 years
Number of subjects: 48834
Study 28682183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use at baseline
Number of subjects: 48834
Study 28682183 — intervention group
Group type: COMPARATOR
Intervention: Comparison group, N = 29,294
Number of subjects: 48834
Study 25956949 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF (Haemodiafiltration)
Number of subjects: 51
Study 25956949 — intervention group
Group type: COMPARATOR
Intervention: HD (High-flux haemodialysis)
Number of subjects: 51
Study 22354337 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-video task
Number of subjects: 60
Study 22354337 — intervention group
Group type: COMPARATOR
Intervention: Regular practical tutoring
Number of subjects: 60
Study 21302036 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPRD-AM1 (250 mg×2) with metronidazole (200 mg×2)
Number of subjects: 11
Study 21302036 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (200 mg×2) alone
Number of subjects: 11
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002% chlorhexidine for 15 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002% chlorhexidine for 60 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine for 60 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine for 60 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine for 60 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine for 60 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine for 15 s
Number of subjects: 0
Study 19758257 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 17009630 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment
Number of subjects: 0
Study 17009630 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 0
Study 12657164 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus SU5416 (VEGF receptor tyrosine kinase inhibitor)
Number of subjects: 23
Study 12657164 — intervention group
Group type: COMPARATOR
Intervention: Standard of care chemotherapy
Number of subjects: 23
Study 10933368 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen use
Number of subjects: 1134
Study 10933368 — intervention group
Group type: COMPARATOR
Intervention: Estrogen nonuse (Control)
Number of subjects: 1134
Study 8623068 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement by 14 examiners using three different instruments
Number of subjects: 18
Study 2169702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 24
Study 2169702 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran
Number of subjects: 24
Study 2169702 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 24
Study 6454395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with 13‐cis retinoic acid
Number of subjects: 18
Study 6454395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 31734573 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized interpretation bias modification (CBM‐I) training, four sessions over a 2-week period
Number of subjects: 0
Study 31734573 — intervention group
Group type: COMPARATOR
Intervention: Computerized 'sham' training (control condition), four sessions over a 2-week period
Number of subjects: 0
Study 30910894 — intervention group
Group type: EXPERIMENTAL
Intervention: DSTA4637S (5, 15, 50, 100, and 150 mg/kg)
Number of subjects: 30
Study 30910894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28328705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 650 nm, administered every other day for 17 weeks
Number of subjects: 0
Study 28328705 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 0
Study 25829373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin (4 g/6 h)
Number of subjects: 0
Study 25829373 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g/8 h)
Number of subjects: 0
Study 23949025 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with sequential target presentation
Number of subjects: 31
Study 23949025 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted therapy with random target presentation
Number of subjects: 31
Study 21120558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 16
Study 21120558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 16
Study 19549186 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (50 U)
Number of subjects: 158
Study 19549186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 17655805 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Number of subjects: 18
Study 17655805 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (20 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Number of subjects: 18
Study 17655805 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS (10 sessions)
Number of subjects: 18
Study 17655805 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS (20 sessions)
Number of subjects: 18
Study 15175560 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (large intravenous doses)
Number of subjects: 6
Study 15175560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation treatment with high-dose Ara-C
Number of subjects: 0
Study 11355926 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic or autologous transplantation
Number of subjects: 0
Study 11355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk patients
Number of subjects: 0
Study 9935255 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin (200 mg) with Morphine (0.15 mg/kg)
Number of subjects: 19
Study 9935255 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 19
Study 9052509 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole therapy for eight weeks
Number of subjects: 22
Study 9052509 — intervention group
Group type: COMPARATOR
Intervention: Control group (moderate GER disease)
Number of subjects: 22
Study 2476613 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily
Number of subjects: 24
Study 2476613 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg twice daily
Number of subjects: 24
Study 2476613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 24
Study 2476613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 786379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral papaverine (300 mg b.i.d.)
Number of subjects: 21
Study 786379 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study 31120988 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm NaOCl
Number of subjects: 14
Study 31120988 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 ppm aqueous-O3
Number of subjects: 14
Study 31120988 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppm PAA
Number of subjects: 14
Study 31120988 — intervention group
Group type: COMPARATOR
Intervention: Positive control (contaminated with feces-Salmonella mixture, not exposed to disinfectants)
Number of subjects: 14
Study 31120988 — intervention group
Group type: COMPARATOR
Intervention: Negative control (laboratory blank, inoculated only with sterile water)
Number of subjects: 14
Study 27966225 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 7
Study 27966225 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP)
Number of subjects: 7
Study 27966225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLYC)
Number of subjects: 7
Study 27966225 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Glycopyrrolate (PROP+GLYC)
Number of subjects: 7
Study 25997044 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 84
Study 25997044 — intervention group
Group type: COMPARATOR
Intervention: Blended Learning (BL)
Number of subjects: 84
Study 23969029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based, Internet-mediated intervention (n=111)
Number of subjects: 229
Study 23969029 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=118)
Number of subjects: 229
Study 21471765 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT intervention (n = 39)
Number of subjects: 75
Study 21471765 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 36)
Number of subjects: 75
Study 19308305 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 19308305 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab in treatment-naive patients with highly active disease
Number of subjects: 0
Study 19308305 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab in patients with highly active disease despite IFNbeta-1a treatment
Number of subjects: 0
Study 16908773 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n = 598)
Number of subjects: 1197
Study 16908773 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (n = 599)
Number of subjects: 1197
Study 15280971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 26
Study 15280971 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic hemoclip placement (EHP)
Number of subjects: 26
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine plus ritonavir
Number of subjects: 181
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus nelfinavir
Number of subjects: 181
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine plus nelfinavir
Number of subjects: 181
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus nevirapine plus nelfinavir
Number of subjects: 181
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine plus lamivudine plus nelfinavir (bid)
Number of subjects: 181
Study 10954886 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine plus lamivudine plus nelfinavir (tid)
Number of subjects: 181
Study 9327686 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 199
Study 9327686 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 199
Study 8350329 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin (1 mg)
Number of subjects: 16
Study 8350329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2871058 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.4 mg/day
Number of subjects: 7
Study 2871058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7